Job title: VP, Head of Market Access
Frank Zhang is currently VP, Head of Market Access at uniQure, a leading gene therapy company. Prior to joining uniQure, Frank was VP Market Access – Global Strategy and US at Alnylam Pharmaceticals, a Cambridge based company leading RNAi technology. He led the launch of Onpattro with over 15 innovative value-based agreements with major US plans. Frank was the Head of Global Pricing and Market Access for Immunology and inflammation franchise of Celgene Corporation from 2010 to 2017. His responsibilities covered five key global functions for Celgene I&I, including Pricing and Market Access, Global Health Economics, Global Outcomes Research, Patient Reported Outcomes (PRO), and Strategic Data Analytics. With his leadership, Otezla was approved for pricing and reimbursement in over 20 countries within 2-year of global launch, and was the most successful commercial launch in immunology at that time. Prior to Celgene, Frank led global Pricing and Health Economics for J&J’s Virology Franchise with successful launch of Incivo/Incivek and Intelence. He was US Outcomes Research lead for Concerta and Effexor in earlier part of his career. Frank is a physician by training with a Master of Public Health degree from Yale University.
‘IMPACCT’ Panel Discussion: Looking Outwards – Demonstrating Product Value & Improved Care Delivery with Real World Evidence 4:00 pm
• Developing a suitable evidence framework to demonstrate product value and differentiation • Addressing external stakeholders’ (payors, providers and patients) concerns as they increasingly seek to understand the effects of new products in the real-world setting • Supporting decision-makers and payors with evidence that is better tailored to help them determine reimbursement policies and insurance…Read more
day: Day Two
What Does it Take to Substantiate a Million-Dollar Price Tag in Gene Therapy? 3:30 pm
• Exploring the challenges with gene therapy market access • Discussing how evidence requirements are more rigorous in gene therapy • Establishing a very different business model for gene therapiesRead more
day: Day Two